RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $37

Benzinga Newsdesk www.benzinga.com Positive 89.5%

Neg 0% Neu 0% Pos 89.5%

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $37.